CLEVELAND, May 22, 2019 /PRNewswire/ -- ViewRay, Inc.
(Nasdaq: VRAY) announced today that the clinical team at Siteman
Cancer Center at Barnes-Jewish Hospital and Washington
University School of Medicine in St. Louis has treated
its 1,000th patient using MRIdian MR-guided radiation
therapy.
Siteman Cancer Center helped pioneer MR-guided radiation
therapy, becoming the first center to treat patients with MRIdian
in January 2014. Siteman also leads
the industry as the first to perform adaptive radiation therapy
under MR-guidance. MRIdian's on-table adaptive capability and
automated beam gating, now routinely practiced at Siteman, allows
clinicians to personalize the radiation delivery by adapting to
daily changes in a patient's anatomy, while its real-time tissue
tracking and beam control allow greater precision to the delivery
of radiation therapy. As the use of MR-guided radiation therapy
expanded, Siteman acquired a second MRIdian System – the MRIdian
Linac – in November 2017, following
FDA-clearance of this next-generation technology from ViewRay. The
new technology features MRI-guidance combined with linear
accelerator delivery.
"We commend the Siteman team for its continued adoption and
advancement of innovative technology to further patient care, and
congratulate them on reaching this exciting milestone," said
Scott Drake, President and Chief
Executive Officer of ViewRay. "The center's trailblazing research
and cutting-edge treatments have played a big role in the clinical
acceptance and growing adoption of MRI-guided radiation therapy,
which, in turn, has benefitted not just the 1,000 cancer patients
at Siteman but many others around the world."
"The location of tumors in the body can fluctuate slightly in
response to subtle movements, such as breathing, potentially
disrupting the precise target of a radiation beam," said
Jeff Michalski, M.D., Carlos A.
Perez Distinguished Professor, Vice Chair and Director of Clinical
Programs in Radiation Oncology at Siteman Cancer Center and
Washington University School of
Medicine. "MR-guided radiation therapy allows us to visualize and
precisely track the contours of a patient's tumor as radiation
therapy is being delivered. With this enhanced visibility, we can
quickly adjust the dose of radiation in real time to account for
changes in the position of a tumor. This capability helps to ensure
that the maximum dose reaches the tumor and incidental exposure to
surrounding healthy tissues is minimized."
Clinicians and researchers at Siteman have been active in
sharing their research and clinical experience to further the
practice of MRI-guided radiation therapy. To date, the team has
published nearly 40 manuscripts in peer-reviewed journals and
presented data at more than 100 major medical meetings,
highlighting its MRI-guided radiation therapy experience. At
Siteman, MRI-guided radiation therapy is involved in the treatment
of patients whose tumors lie near critical anatomical structures
and is being evaluated in clinical trials for pancreas, breast and
lung cancers.
About ViewRay
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets
the MRIdian® radiation therapy system. MRIdian is built upon a
proprietary high-definition MR imaging system designed from the
ground up to address the unique challenges and clinical workflow
for advanced radiation oncology. Unlike MR systems used in
diagnostic radiology, MRIdian's high-definition MR was purposely
built to deliver high-precision radiation without unnecessary beam
distortion, and consequently, help to mitigate skin toxicity and
other safety concerns that may otherwise arise when high magnetic
fields interact with radiation beams. ViewRay and MRIdian are
registered trademarks of ViewRay, Inc.
Intended Use: The MRIdian Linac System, with magnetic
resonance imaging capabilities, is intended to provide stereotactic
radiosurgery and precision radiotherapy for lesions, tumors, and
conditions anywhere in the body where radiation treatment is
indicated.
Forward Looking Statements: This press release contains
forward-looking statements. Statements in this press release that
are not purely historical are forward-looking statements. These
statements are subject to risks and uncertainties that could cause
future results to differ materially from those referenced.
Forward-looking statements include, but are not limited to,
statements about ViewRay's financial results and market acceptance
of ViewRay's existing products, future products or technology.
Words such as "could," "anticipates," "expects," "outlook,"
"intends," "plans," "believes," "seeks," "vision," "estimates,"
"may," "will," "future," "horizon," "aiming," "driving," "target"
(or variations of them) and similar statements, are forward-looking
statements. Forward-looking statements involve risks, uncertainties
and assumptions that are difficult to predict and could cause
ViewRay's results to differ materially from those presented. These
risks, uncertainties and assumptions include, but are not limited
to, changes in: the regulatory environment; global economics; trade
compliance requirements, duties or tariffs; third-party
reimbursement levels; currency exchange rates; taxation, healthcare
law, and product clearance requirements, as well as those related
to: adverse publicity about ViewRay and our products; our reliance
on sole or limited source suppliers; our ability to commercialize
our products successfully; the impact of competitive products and
pricing, and all other risks listed from time to time in the
company's filings with the Securities and Exchange Commission,
available at www.sec.gov, which are incorporated into this
Forward-Looking Statements disclosure by this reference. These
forward-looking statements are made as of the date of this press
release, and ViewRay assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results differ from those projected in the forward-looking
statements, except as required by law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/worlds-first-mridian-center-treats-1-000th-patient-with-mri-guided-radiation-therapy-300854382.html
SOURCE ViewRay, Inc.